<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14389">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00306163</url>
  </required_header>
  <id_info>
    <org_study_id>BY9010/NL-101</org_study_id>
    <nct_id>NCT00306163</nct_id>
  </id_info>
  <brief_title>Responsiveness of Lower Airways in Adult Patients (18-60 Years) With Stable Asthma After Treatment With Ciclesonide and Fluticasone Propionate (BY9010/NL-101)</brief_title>
  <official_title>Nebulizer Trial: Evaluation of the Influence of Particle Size of Aerosolized AMP on Bronchial Responsiveness in Patients With Asthma and the Effects of Treatment With Ciclesonide Versus Fluticasone.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <authority>Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare the responsiveness of lower airways in adult patients
      with stable asthma after treatment with ciclesonide and fluticasone propionate. Treatment
      medication will be administered as follows: ciclesonide will be inhaled once daily at one
      dose level, fluticasone propionate will be inhaled twice daily at one dose level. The study
      duration consists of a baseline period (5 weeks) and a treatment period (5 weeks). The study
      will provide further data on safety and tolerability of ciclesonide.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>PC20 AMP (Post-treatment Compared to Baseline)</measure>
    <time_frame>Baseline and 5 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mean change of Provocative concentration of Adenosine-5'-monophosphate (PC20 AMP) leading to a 20 percent decrease in Forced expiratory volume in one second (FEV1) between post-treatment and baseline using two different particle sizes.
Small particles = Mass mean aerodynamic diameter (MMAD) of approximately 1.04-1.08 micron
Large particles = MMAD of approximately 9.9-10.6 micron</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Δ (FVC/SVC) at PC20 (AMP)</measure>
    <time_frame>Baseline and 5 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change between baseline and post-treatment of the ratio of Forced Vital Capacity (FVC) and Slow Vital Capacity at PC20. Measured with either small or large partical size AMP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>5 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ciclesonide 160 µg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fluticasone 100 µg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciclesonide</intervention_name>
    <description>inhaled Ciclesonide 160 µg, once daily in the morning</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluticasone</intervention_name>
    <description>inhaled Fluticasone 100 µg, twice daily</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          -  History of bronchial asthma

          -  FEV1 &gt; 1.20 L

          -  Positive Skin Prick Test

          -  Not more than 500 mcg/day fluticasone propionate or equivalent for at least 28 days
             prior to baseline visit

        Main Exclusion Criteria:

          -  Clinically relevant abnormal laboratory values

          -  Concomitant severe diseases, diseases expected to interfere with the outcome of the
             study and diseases which are contra-indications for the use of inhaled steroids

          -  Chronic obstructive pulmonary disease (COPD) and /or other relevant lung diseases

          -  One asthma exacerbation within 2 months or more than 3 exacerbations within the last
             year prior to baseline visit

          -  Current smokers or ex-smokers with more than 10 pack years, or having smoked within 1
             year prior to baseline visit

          -  Positive response to saline challenge at baseline visits

          -  Positive bronchial hyperresponsiveness
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>D.S. Postma, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Groningen, The Netherlands</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed</name>
      <address>
        <city>RB Groningen</city>
        <zip>9700</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>April 2010</verification_date>
  <lastchanged_date>May 4, 2012</lastchanged_date>
  <firstreceived_date>March 22, 2006</firstreceived_date>
  <firstreceived_results_date>April 6, 2010</firstreceived_results_date>
  <responsible_party>
    <name_title>Nycomed GmbH</name_title>
    <organization>Nycomed</organization>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>AMP</keyword>
  <keyword>Ciclesonide</keyword>
  <keyword>Fluticasone propionate</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ciclesonide</mesh_term>
    <mesh_term>Fluticasone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 101 subjects gave Informed Consent. 64 subjects did not enter or discontinued the study due to various reasons.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ciclesonide</title>
          <description>160 µg, once daily</description>
        </group>
        <group group_id="P2">
          <title>Fluticasone</title>
          <description>100 µg, twice daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ciclesonide</title>
          <description>160 µg, once daily</description>
        </group>
        <group group_id="B2">
          <title>Fluticasone</title>
          <description>100 µg, twice daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="19"/>
                <measurement group_id="B2" value="18"/>
                <measurement group_id="B3" value="37"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>Statistics for the total value were not available. The cited numbers are the results of manual calculations.</description>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="39.61" spread="10.50" lower_limit="32.54" upper_limit="46.64"/>
                <measurement group_id="B2" value="46.02" spread="9.80" lower_limit="37.85" upper_limit="55.52"/>
                <measurement group_id="B3" value="42.25" spread="10.16" lower_limit="37.58" upper_limit="51.75"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="13"/>
                <measurement group_id="B2" value="8"/>
                <measurement group_id="B3" value="21"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
                <measurement group_id="B2" value="10"/>
                <measurement group_id="B3" value="16"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>PC20 AMP (Post-treatment Compared to Baseline)</title>
        <description>Mean change of Provocative concentration of Adenosine-5'-monophosphate (PC20 AMP) leading to a 20 percent decrease in Forced expiratory volume in one second (FEV1) between post-treatment and baseline using two different particle sizes.
Small particles = Mass mean aerodynamic diameter (MMAD) of approximately 1.04-1.08 micron
Large particles = MMAD of approximately 9.9-10.6 micron</description>
        <time_frame>Baseline and 5 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analyses on treatment effects were performed on all subjects who reached a PC20&lt;640mg/mL.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide</title>
            <description>160 µg, once daily</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone</title>
            <description>100 µg, twice daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>PC20 AMP (Post-treatment Compared to Baseline)</title>
            <description>Mean change of Provocative concentration of Adenosine-5'-monophosphate (PC20 AMP) leading to a 20 percent decrease in Forced expiratory volume in one second (FEV1) between post-treatment and baseline using two different particle sizes.
Small particles = Mass mean aerodynamic diameter (MMAD) of approximately 1.04-1.08 micron
Large particles = MMAD of approximately 9.9-10.6 micron</description>
            <units>Logarithm (mg/mL)</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Baseline PC20 small-particle AMP</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4.9" spread="3.7"/>
                  <measurement group_id="O2" value="5.2" spread="2.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline PC20 large-particle AMP</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.7" spread="2.6"/>
                  <measurement group_id="O2" value="3.0" spread="2.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Post-Treatment PC20 small-particle AMP</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6.6" spread="2.0"/>
                  <measurement group_id="O2" value="6.0" spread="2.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Post-Treatment PC20 large-particle AMP</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4.5" spread="2.3"/>
                  <measurement group_id="O2" value="4.3" spread="2.4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Δ (FVC/SVC) at PC20 (AMP)</title>
        <description>Change between baseline and post-treatment of the ratio of Forced Vital Capacity (FVC) and Slow Vital Capacity at PC20. Measured with either small or large partical size AMP.</description>
        <time_frame>Baseline and 5 weeks</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety and Tolerability</title>
        <time_frame>5 weeks</time_frame>
        <safety_issue>Yes</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Ciclesonide</title>
          <description>160 µg, once daily</description>
        </group>
        <group group_id="E2">
          <title>Fluticasone</title>
          <description>100 µg, twice daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain armpit</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Common cold</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Inflammation of the throat</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Respiratory Medical Advisor</name_or_title>
      <organization>Nycomed GmbH</organization>
      <phone>0049-7531-840</phone>
      <email>clinicaltrials@nycomed.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
